CN Patent

CN113304166B — 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途

Assigned to Henan Genuine Biotech Co Ltd · Expires 2022-10-14 · 4y expired

What this patent protects

式(I)所示的化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，所述式(I)化合物用于治疗新冠状病毒肺炎病人，在病毒核酸试验转阴率、转阴疗程、治愈出院时间都显示明显优势。

USPTO Abstract

式(I)所示的化合物或其药学上可接受的盐在制备预防或治疗冠状病毒感染性疾病的药物中的用途，所述式(I)化合物用于治疗新冠状病毒肺炎病人，在病毒核酸试验转阴率、转阴疗程、治愈出院时间都显示明显优势。

Drugs covered by this patent

Patent Metadata

Patent number
CN113304166B
Jurisdiction
CN
Classification
—
Expires
2022-10-14
Drug substance claim
No
Drug product claim
No
Assignee
Henan Genuine Biotech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.